Iben Kümler

Summary

Affiliation: Copenhagen University Hospital
Country: Denmark

Publications

  1. doi request reprint A systematic review of dual targeting in HER2-positive breast cancer
    Iben Kümler
    Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, DK 2730 Herlev, Denmark Electronic address
    Cancer Treat Rev 40:259-70. 2014
  2. doi request reprint A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer
    Iben Kümler
    Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, 2730, Herlev, Denmark
    Breast Cancer Res Treat 138:347-58. 2013
  3. doi request reprint Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
    Dorte L Nielsen
    Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, DK 2730 Herlev, Denmark
    Breast 22:1-12. 2013
  4. doi request reprint A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer
    Pia Bükmann Larsen
    Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark
    Cancer Treat Rev 39:720-7. 2013
  5. doi request reprint Trials of bevacizumab in breast cancer--a safety review
    Iben Kümler
    University of Copenhagen, Herlev Hospital, Department of Oncology, Herlev Ringvej 75, DK 2730, Herlev, Denmark
    Expert Opin Drug Saf 11:S37-48. 2012

Detail Information

Publications5

  1. doi request reprint A systematic review of dual targeting in HER2-positive breast cancer
    Iben Kümler
    Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, DK 2730 Herlev, Denmark Electronic address
    Cancer Treat Rev 40:259-70. 2014
    ..The present review addresses efficacy and toxicity of dual targeting in HER2-positive breast cancer...
  2. doi request reprint A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer
    Iben Kümler
    Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, 2730, Herlev, Denmark
    Breast Cancer Res Treat 138:347-58. 2013
    ..However, a large proportion of patients do not respond, thus emphasizing the need for a biomarker predictive of response to irinotecan in order to introduce this drug as the standard treatment for MBC...
  3. doi request reprint Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
    Dorte L Nielsen
    Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, DK 2730 Herlev, Denmark
    Breast 22:1-12. 2013
    ..The future challenges include understanding HER2 functions, designing rational combinations and optimal selection of patients...
  4. doi request reprint A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer
    Pia Bükmann Larsen
    Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark
    Cancer Treat Rev 39:720-7. 2013
    ..The choice of chemotherapy to accompany the blockade is not obvious and we do not know if dual is better than single blockade. Further clinical trials are urgently needed...
  5. doi request reprint Trials of bevacizumab in breast cancer--a safety review
    Iben Kümler
    University of Copenhagen, Herlev Hospital, Department of Oncology, Herlev Ringvej 75, DK 2730, Herlev, Denmark
    Expert Opin Drug Saf 11:S37-48. 2012
    ..Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, has provided promise for continued gains in therapy efficacy...